PL417066A1 - Inhibitory arginazy oraz ich zastosowania terapeutyczne - Google Patents

Inhibitory arginazy oraz ich zastosowania terapeutyczne

Info

Publication number
PL417066A1
PL417066A1 PL417066A PL41706616A PL417066A1 PL 417066 A1 PL417066 A1 PL 417066A1 PL 417066 A PL417066 A PL 417066A PL 41706616 A PL41706616 A PL 41706616A PL 417066 A1 PL417066 A1 PL 417066A1
Authority
PL
Poland
Prior art keywords
arginase
application
arginase inhibitors
therapeutical applications
compounds
Prior art date
Application number
PL417066A
Other languages
English (en)
Inventor
Roman Błaszczyk
Joanna Brzezińska
Anna Gzik
Marek Dzięgielewski
Bartłomiej Borek
Adam Gołębiowski
Julita Nowicka
Original Assignee
Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością filed Critical Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL417066A priority Critical patent/PL417066A1/pl
Priority to ES17721137T priority patent/ES2834065T3/es
Priority to LTEP17721137.2T priority patent/LT3452485T/lt
Priority to NZ746211A priority patent/NZ746211B2/en
Priority to HRP20201821TT priority patent/HRP20201821T1/hr
Priority to DK17721137.2T priority patent/DK3452485T3/da
Priority to KR1020187034423A priority patent/KR102374788B1/ko
Priority to EP17721137.2A priority patent/EP3452485B1/en
Priority to AU2017259887A priority patent/AU2017259887B2/en
Priority to BR112018072545-5A priority patent/BR112018072545B1/pt
Priority to JP2018556824A priority patent/JP6971477B2/ja
Priority to MX2018013387A priority patent/MX378806B/es
Priority to PE2018002300A priority patent/PE20181924A1/es
Priority to PL17721137T priority patent/PL3452485T3/pl
Priority to HUE17721137A priority patent/HUE052468T2/hu
Priority to SG11201807974QA priority patent/SG11201807974QA/en
Priority to CA3022482A priority patent/CA3022482C/en
Priority to CN201780041841.9A priority patent/CN109415387B/zh
Priority to PCT/EP2017/060413 priority patent/WO2017191130A2/en
Priority to SI201730505T priority patent/SI3452485T1/sl
Priority to US15/584,193 priority patent/US10391077B2/en
Publication of PL417066A1 publication Critical patent/PL417066A1/pl
Priority to PH12018501976A priority patent/PH12018501976A1/en
Priority to IL262387A priority patent/IL262387B/en
Priority to SA518400356A priority patent/SA518400356B1/ar
Priority to CL2018003132A priority patent/CL2018003132A1/es
Priority to CONC2018/0013077A priority patent/CO2018013077A2/es
Priority to US16/540,747 priority patent/US10912755B2/en
Priority to US17/168,291 priority patent/US12053451B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem zgłoszenia są małocząsteczkowe związki terapeutyczne, które są mocnymi inhibitorami aktywności arginazy 1 i arginazy 2. Ponadto zgłoszenie obejmuje też sposób hamowania arginazy I, arginazy II lub ich kombinacji w komórce. Zgłoszenie ujawnia też kompozycje farmaceutyczne, zawierające związki i sposoby stosowania związków do leczenia lub zapobiegania chorobie lub stanowi związanemu z aktywnością arginazy.
PL417066A 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne PL417066A1 (pl)

Priority Applications (28)

Application Number Priority Date Filing Date Title
PL417066A PL417066A1 (pl) 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne
US15/584,193 US10391077B2 (en) 2016-05-04 2017-05-02 Arginase inhibitors and their therapeutic applications
PL17721137T PL3452485T3 (pl) 2016-05-04 2017-05-02 Inhibitory arginazy oraz ich zastosowania terapeutyczne
NZ746211A NZ746211B2 (en) 2017-05-02 Arginase inhibitors and their therapeutic applications
HRP20201821TT HRP20201821T1 (hr) 2016-05-04 2017-05-02 Inhibitori arginaze i njihove terapeutske primjene
SG11201807974QA SG11201807974QA (en) 2016-05-04 2017-05-02 Arginase inhibitors and their therapeutic applications
KR1020187034423A KR102374788B1 (ko) 2016-05-04 2017-05-02 아르기나제 저해제 및 이의 치료적 용도
EP17721137.2A EP3452485B1 (en) 2016-05-04 2017-05-02 Arginase inhibitors and their therapeutic applications
AU2017259887A AU2017259887B2 (en) 2016-05-04 2017-05-02 Arginase inhibitors and their therapeutic applications
BR112018072545-5A BR112018072545B1 (pt) 2016-05-04 2017-05-02 Inibidores da arginase e suas aplicações terapêuticas
JP2018556824A JP6971477B2 (ja) 2016-05-04 2017-05-02 アルギナーゼ阻害剤およびそれらの治療適用
MX2018013387A MX378806B (es) 2016-05-04 2017-05-02 Inhibidores de la arginasa y sus aplicaciones terapéuticas.
PE2018002300A PE20181924A1 (es) 2016-05-04 2017-05-02 Inhibidores de la arginasa y sus aplicaciones terapeuticas
ES17721137T ES2834065T3 (es) 2016-05-04 2017-05-02 Inhibidores de arginasa y sus aplicaciones terapéuticas
HUE17721137A HUE052468T2 (hu) 2016-05-04 2017-05-02 Arginázgátlók és terápiás alkalmazásaik
DK17721137.2T DK3452485T3 (da) 2016-05-04 2017-05-02 Arginasehæmmere og deres terapeutiske anvendelser
CA3022482A CA3022482C (en) 2016-05-04 2017-05-02 Arginase inhibitors and their therapeutic applications
CN201780041841.9A CN109415387B (zh) 2016-05-04 2017-05-02 精氨酸酶抑制剂及其治疗应用
PCT/EP2017/060413 WO2017191130A2 (en) 2016-05-04 2017-05-02 Arginase inhibitors and their therapeutic applications
SI201730505T SI3452485T1 (sl) 2016-05-04 2017-05-02 Inhibitorji arginaze in njihova terapevtska uporaba
LTEP17721137.2T LT3452485T (lt) 2016-05-04 2017-05-02 Arginazės inhibitoriai ir jų terapinis taikymas
PH12018501976A PH12018501976A1 (en) 2016-05-04 2018-09-13 Arginase inhibitors and their therapeutic applications
IL262387A IL262387B (en) 2016-05-04 2018-10-15 Arginase inhibitors and treatment applications thereof
SA518400356A SA518400356B1 (ar) 2016-05-04 2018-11-01 مثبطات الأرجيناز واستخداماتها العلاجية
CL2018003132A CL2018003132A1 (es) 2016-05-04 2018-11-05 Inhibidores de la arginasa y sus aplicaciones terapéuticas.
CONC2018/0013077A CO2018013077A2 (es) 2016-05-04 2018-12-03 Inhibidores de la arginasa y sus aplicaciones terapéuticas
US16/540,747 US10912755B2 (en) 2016-05-04 2019-08-14 Arginase inhibitors and their therapeutic applications
US17/168,291 US12053451B2 (en) 2016-05-04 2021-02-05 Arginase inhibitors and their therapeutic applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL417066A PL417066A1 (pl) 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne

Publications (1)

Publication Number Publication Date
PL417066A1 true PL417066A1 (pl) 2017-11-06

Family

ID=60190450

Family Applications (2)

Application Number Title Priority Date Filing Date
PL417066A PL417066A1 (pl) 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne
PL17721137T PL3452485T3 (pl) 2016-05-04 2017-05-02 Inhibitory arginazy oraz ich zastosowania terapeutyczne

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17721137T PL3452485T3 (pl) 2016-05-04 2017-05-02 Inhibitory arginazy oraz ich zastosowania terapeutyczne

Country Status (24)

Country Link
US (3) US10391077B2 (pl)
EP (1) EP3452485B1 (pl)
JP (1) JP6971477B2 (pl)
KR (1) KR102374788B1 (pl)
CN (1) CN109415387B (pl)
AU (1) AU2017259887B2 (pl)
BR (1) BR112018072545B1 (pl)
CA (1) CA3022482C (pl)
CL (1) CL2018003132A1 (pl)
CO (1) CO2018013077A2 (pl)
DK (1) DK3452485T3 (pl)
ES (1) ES2834065T3 (pl)
HR (1) HRP20201821T1 (pl)
HU (1) HUE052468T2 (pl)
IL (1) IL262387B (pl)
LT (1) LT3452485T (pl)
MX (1) MX378806B (pl)
PE (1) PE20181924A1 (pl)
PH (1) PH12018501976A1 (pl)
PL (2) PL417066A1 (pl)
SA (1) SA518400356B1 (pl)
SG (1) SG11201807974QA (pl)
SI (1) SI3452485T1 (pl)
WO (1) WO2017191130A2 (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024209358A1 (en) 2023-04-06 2024-10-10 Molecure S.A. Process for the production of (1r,2s,5r)-1-amino-5-[2-(dihydroxyboranyl)ethyl]-2-[(dimethylamino)methyl]cyclohexane-1-carboxylic acid

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2632927T3 (en) 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
SG11201802961PA (en) 2015-10-30 2018-05-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
NZ745681A (en) 2016-03-07 2022-05-27 Agrofresh Inc Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
NZ754364A (en) 2016-12-22 2023-04-28 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
SG11202007739XA (en) 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
KR102656571B1 (ko) * 2018-03-05 2024-04-11 아르커스 바이오사이언시즈 인코포레이티드 아르기나아제 억제제
WO2019177873A1 (en) 2018-03-13 2019-09-19 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
EP3774843B1 (en) * 2018-03-29 2022-05-25 Molecure SA Dipeptide piperidine derivatives
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
ES3034676T3 (en) 2018-11-16 2025-08-21 Arcus Biosciences Inc Inhibitors of arg1 and/or arg2
US12240867B2 (en) 2018-12-18 2025-03-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2021096542A1 (en) 2019-11-12 2021-05-20 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing ido antagonist prodrugs useful in the treatment of cancer and methods thereof
US20230140132A1 (en) * 2020-01-07 2023-05-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
EP1049660A1 (en) 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
EP1604978A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals Trans pyrrolidinyl derivatives and their pharmaceutical uses
EP1604977A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals CIS pyrrolidinyl derivatives and their uses
EP2083812B1 (en) 2006-11-21 2017-04-05 Rijksuniversiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
HRP20191433T1 (hr) 2009-01-26 2019-11-15 Univ Pennsylvania Inhibitori arginaze i metode primjene
US9040703B2 (en) 2010-04-22 2015-05-26 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
DK2632927T3 (en) 2010-10-26 2016-04-11 Mars Inc Boronates AS ARGINSASEINHIBITORER
EP2658580A4 (en) 2010-12-31 2014-07-23 Corridor Pharmaceuticals Inc ARGINE STARTER AND USE METHOD
US9266908B2 (en) 2011-10-19 2016-02-23 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
AU2013249790B2 (en) * 2012-04-18 2018-01-25 Mars, Incorporated Ring constrained analogs as Arginase inhibitors
CA2874800C (en) 2012-07-13 2021-04-06 Janssen R&D Ireland Macrocyclic purines for the treatment of viral infections
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2016281620B2 (en) 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
SG11201802961PA (en) 2015-10-30 2018-05-30 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2017356942A1 (en) 2016-11-08 2019-05-23 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
AU2019211067A1 (en) 2018-01-28 2020-08-13 Universite De Geneve Arginase suppression for cancer treatment

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024209358A1 (en) 2023-04-06 2024-10-10 Molecure S.A. Process for the production of (1r,2s,5r)-1-amino-5-[2-(dihydroxyboranyl)ethyl]-2-[(dimethylamino)methyl]cyclohexane-1-carboxylic acid

Also Published As

Publication number Publication date
DK3452485T3 (da) 2020-11-09
CN109415387A (zh) 2019-03-01
WO2017191130A2 (en) 2017-11-09
US12053451B2 (en) 2024-08-06
US20170319536A1 (en) 2017-11-09
MX2018013387A (es) 2019-02-28
HRP20201821T1 (hr) 2021-04-16
KR20190015250A (ko) 2019-02-13
US20210260019A1 (en) 2021-08-26
AU2017259887B2 (en) 2022-03-17
ES2834065T3 (es) 2021-06-16
US10391077B2 (en) 2019-08-27
SI3452485T1 (sl) 2021-01-29
CN109415387B (zh) 2021-08-27
LT3452485T (lt) 2020-12-28
KR102374788B1 (ko) 2022-03-15
SA518400356B1 (ar) 2022-01-19
BR112018072545A2 (pt) 2019-06-25
CL2018003132A1 (es) 2019-02-22
WO2017191130A3 (en) 2017-12-14
PL3452485T3 (pl) 2021-04-19
PE20181924A1 (es) 2018-12-11
NZ746211A (en) 2024-12-20
EP3452485A2 (en) 2019-03-13
HUE052468T2 (hu) 2021-04-28
AU2017259887A1 (en) 2018-09-27
PH12018501976A1 (en) 2019-07-01
CA3022482A1 (en) 2017-11-09
JP6971477B2 (ja) 2021-11-24
SG11201807974QA (en) 2018-10-30
IL262387B (en) 2021-10-31
JP2019518726A (ja) 2019-07-04
CO2018013077A2 (es) 2019-04-30
MX378806B (es) 2025-03-11
IL262387A (en) 2018-12-31
CA3022482C (en) 2024-06-11
US20190365701A1 (en) 2019-12-05
WO2017191130A4 (en) 2018-03-01
EP3452485B1 (en) 2020-09-09
US10912755B2 (en) 2021-02-09
BR112018072545B1 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
PL417066A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX384792B (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
JOP20200001A1 (ar) كاربوكسأميدات بوصفها معدلات لقنوات الصوديوم
MX392026B (es) Compuestos heterocíclicos como inmunomoduladores.
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
MX343534B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
ZA201904522B (en) Heterocyclic inhibitors of mct4
EA201990400A1 (ru) Соединения и композиции и их применение
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
JOP20190262B1 (ar) مثبطات بيرازول magl
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2018001733A (es) Compuestos heterocíclicos de fumagillol y métodos de elaboración y uso de los mismos.
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
JOP20190053A1 (ar) مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
BR112017018198A2 (pt) inibição da atividade de olig2
EP4477265A3 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
EA201990399A1 (ru) Соединения, композиции и их применение